Skip to main content

Psychedelic Capital 2020: A Dynamic Year in Review for the Psychedelic Renaissance

By: Issuewire
Psychedelic Capital November 30th 2020

Between massive market growth for the growing list of publicly traded psychedelic stocks to monumental legislative wins, the psychedelic medicine movement is making historic progress.

Toronto, Nov 26, 2020 (Issuewire.com) - While the global Coronavirus pandemic has certainly brought forth unprecedented challenges this year, 2020 has been an equally unprecedented year for the psychedelic renaissance. Between massive market growth for the growing list of publicly traded psychedelic stocks to monumental legislative wins, the psychedelic medicine movement is making historic progress. Here are three big reasons you won't want to miss the final edition of Psychedelic Capital, the world's premiere psychedelic due diligence conference, for the year 2020. 

Reason #1: Monumental Legislative Victories Spell Promise for Future of Psychedelics

Psychedelics have not only been winning big in capital markets but legislatively as well. In 2020 alone, the world witnessed sweeping drug policy reform, particularly with respect to psychedelic medicine. From Measure 109 passing in Oregon, which allows for legal psilocybin therapy centers in the state, to Therapsil's novel advocacy efforts in helping both palliative and non-palliative patients gain access to psilocybin therapy, it is clear the psychedelic renaissance is here to stay. There's no better time to get involved in the dynamic psychedelic investment landscape than right now. Grab your free ticket to Psychedelic Capital today to get the latest updates and deepest insights from leading experts at the frontlines of drug policy reform. 

Reason #2: Spotlighting Massive 2020 Market Growth for Psychedelic Companies   

This month's conference will spotlight the massive market growth psychedelic companies have witnessed in the year 2020. The mammoth raises witnessed by firms like MindMed (MMED), ATAI Life Sciences (ATAI) and Cybin Corp (CYBN) clearly demonstrate both investors and the world at large are ready to embrace psychedelic medicine. The enormous growth firms like Compass Pathways (CMPS) and MMED have observed alone is incredibly promising for the future of psychedelics.  


Reason #3: November's Psychedelic Capital Features Another All-Star List of Dignitaries & Sponsors

As always, Microdose's premier monthly psychedelic due diligence event convenes the leading experts and thought leaders in the field of psychedelic medicine. November's event features Sam Chapman, the campaign manager for the Yes on Measure 109 Campaign in Oregon, Robin Arnott, CEO of Andromeda Entertainment, the dynamic advocate, author and politician, Dana Larsen, and Joël Brierre, Founder of Kaivalya Kollectiv. Sponsors for this event also include MNP, the leading national accounting, tax and business consulting firm in Canada, Andromeda Entertainment, Kaivalya Kollectiv, and KetaMD.

Other notable speakers include Mitchell Ossak, CEO of Quanta, Warren Gumpel, Co-Founder and CEO of KetaMD, Zappy Zapolin, Co-Founder and Executive Chairman of KetaMD, Maruf Raza, National Director of MNP and Jameson Berkow, Co-Founder and Editor-in-Chief of The Weekly Chronicle, Kathryn Tucker Special Counsel, Emerge Law Group, Brandon Roop Vice President, Investment Banking, Stifel GMP, Dr. Malik Slassi Senior Scientific Advisor, Mindset Pharma, Gregg Peterson CEO, Bexson Biomedical among others. 

The final edition in 2020 of Psychedelic Capital is taking place on Monday, November 30th, 2020 at 1 PM EST. 

You may find free tickets, compliments of our sponsors, by clicking this link.

Psychedelic Capital November 30th 2020Psychedelic Capital November 30th 2020Psychedelic Capital November 30th 2020

Media Contact

Microdose Psychedelic Insights


*****@microdose.buzz

https://microdose.buzz

Source :Microdose Psychedelic Insights

This article was originally published by IssueWire. Read the original article here.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.